All

1256 Expert Conversations

1256 Expert Conversations
Most patients with fatty liver disease & NASH do not have symptoms. Alcohol is often not to blame. 17
How to improve health of your liver? Difficulty to keep low weight. 16
FAQ from patients with fatty liver disease. Life quality, prognosis, alcohol use. 15
Future of liver disease treatment. Xenotransplantation of liver. 14
Coffee reduces risks of liver disease. Coffee and NAFLD prevention. 13
Leading drug candidates for NASH therapy. NAFLD, fatty liver disease treatment. 12
When new drugs will be approved for fatty liver disease? 11
Liver cancer risk and fatty liver disease. Cancer screening in NASH, NAFLD. 10
Hepatic Stellate Cells cause fatty liver disease. NAFLD and NASH causes. 9
Food supplements and generic drugs for NASH and NAFLD. 8
Gut microbiome and fatty liver disease. NAFLD, NASH, and Fecal transplantation. 7
Genetic tests to find risks for liver disease [NAFLD and NASH]. 6
How NASH differs from NAFLD. What drives progression to NASH? 5
Can fatty liver disease be reversed? NAFLD and NASH treatment. 4
Diagnostic tests for fatty liver disease, NAFLD. FibroScan and MR Elastography. 3
Non-obese patients with NAFLD [fatty liver disease]. ‘Lean NASH’. 2
What is Non-Alcoholic Fatty Liver Disease? NAFLD Diagnostic Criteria. 1
Dr. Scott L Friedman. Liver disease, NAFLD, NASH Expert. Biography. 0
Pediatric rheumatology must be better organized. Top expert shares wisdom. 19
Lessons from COVID-19 pandemic. Right and wrong predictions. 18
Patient’s story. Cytokine storm. Cytophagic histiocytic panniculitis. 17
Pediatric arthritis FAQ. Can a child with arthritis lead a normal life? 16
Arthritis in children. FAQ. Nutrition in arthritis. Will my child outgrow arthritis? 15
Pediatric rheumatic disease treatment. ‘Reverse the pyramid’ when choosing treatment. 14
Future of pediatric rheumatology. Early use of biologics instead of ‘treating to target’. 13
Pediatric rheumatic diseases today vs. 20 years ago. Progress in treatment. Paradigm shifts. 12
Genomic sequencing and Cytokine storm susceptibility. Part 2. 11
Cytokine storm. Genetic susceptibility. Part 1. 10
Cytokine storm risk in hospitalized patients with fever. Occam's razor (a diagnostic principle). 9
Macrophage activation syndrome. MAS. Hemophagocytic lymphohistiocytosis. HLH. 8
Cytokine storm treatment. Part 4. ‘Inflammo-stabilization’ strategy. 7
Cytokine storm treatment. Part 3. IL-6, IL-1 inhibitors. Anakinra. Tocilizumab. 6
Cytokine storm treatment. Part 2. JAK inhibitors. Corticosteroids. 5
Cytokine storm treatment. Part 1. Causes:
 Covid-19. CAR T-cell therapy. 4
Multisystem inflammatory syndrome in children. MIS-C. Prognosis and recovery. 3
Multisystem inflammatory syndrome in children. MIS-C. Susceptibility factors. 2
Multisystem inflammatory syndrome in children. MIS-C. Kawasaki disease. 1
Dr. Randy Cron. Pediatric rheumatology, Cytokine storm expert. Biography. 0
Mesothelioma. Clinical case. Example of importance of enrollment into clinical trials. 11
Mesothelioma. Importance 
for patients of enrollment into clinical trials. 10
Recently viewed

Explore Masterclasses by topic